Al-Homood Ibrahim A
College of Medicine, Al Imam Mohammad Ibn Saud Islamic University, P.O. Box 75227, Riyadh, 11578, Saudi Arabia,
Clin Exp Med. 2014 Nov;14(4):355-60. doi: 10.1007/s10238-013-0254-5. Epub 2013 Aug 15.
Large vessel vasculitis represents mainly two main diseases: giant cell arteritis and Takayasu arteritis. Recent advancements in the treatment for different rheumatic diseases refractory to disease-modifying antirheumatic agents with biologic agents have resulted in remarkable efficacy and tolerability. However, treatments for large vessel vasculitis (LVV) with tumor necrosis factor-α inhibitors have yielded conflicting results. Recently, very promising results have been reported in patients treated with tocilizumab. The purpose of this review is to summarize the current treatment strategies of LVV and the recent evidence on the use of tocilizumab in LVV.
巨细胞动脉炎和大动脉炎。近年来，使用生物制剂治疗对改善病情抗风湿药难治的不同风湿性疾病取得了显著疗效和耐受性。然而，使用肿瘤坏死因子-α抑制剂治疗大血管血管炎（LVV）的结果却相互矛盾。最近，使用托珠单抗治疗的患者报告了非常有前景的结果。本综述的目的是总结LVV的当前治疗策略以及托珠单抗在LVV中应用的最新证据。
